
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
    <title>GI Intelligence Terminal</title><script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        :root { --primary: #3498db; --success: #2ecc71; --warning: #ffb300; --bg: #f5f7fa; --text: #2c3e50; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); margin: 0; padding: 8px; }
        .card { background: #fff; border-radius: 12px; padding: 12px; box-shadow: 0 2px 8px rgba(0,0,0,0.05); margin-bottom: 12px; border: 1px solid #e0e0e0; }
        
        /* ğŸ© ë„í‘œ ì¤‘ì•™ ë°°ì¹˜ ìŠ¤íƒ€ì¼ */
        .chart-container { background: #fff; border-radius: 12px; padding: 12px; border: 1px solid #e0e0e0; height: 160px; display: flex; justify-content: center; margin-bottom: 12px; }
        
        .paper-item { margin-bottom: 8px; border-radius: 10px; overflow: hidden; list-style: none; border: 1px solid #eee; }
        summary { padding: 12px; cursor: pointer; outline: none; list-style: none; }
        summary::-webkit-details-marker { display: none; }
        .meta { font-size: 0.7rem; color: #7f8c8d; margin-bottom: 4px; display: flex; align-items: center; gap: 4px; flex-wrap: wrap; }
        .title-row { font-weight: bold; font-size: 0.9rem; line-height: 1.4; display: flex; align-items: flex-start; }
        .arrow-icon { display: inline-block; transition: transform 0.2s; color: var(--primary); margin-right: 6px; flex-shrink: 0; }
        details[open] .arrow-icon { transform: rotate(90deg); }
        .badge { padding: 1px 4px; border-radius: 3px; font-size: 0.6rem; font-weight: bold; color: #fff; }
        .rct { background: #e74c3c; } .gl { background: var(--success); } .if { background: #8e44ad; }
        .content { padding: 12px; background: #f9f9f9; border-top: 1px solid #eee; font-size: 0.85rem; }
        .clinical-note { background: #fff8e1; border-left: 3px solid var(--warning); padding: 10px; border-radius: 6px; margin-bottom: 10px; font-size: 0.8rem; color: #5d4037; }
        .btm-box { background: #ebf5ff; padding: 10px; border-radius: 6px; margin-bottom: 10px; border-left: 3px solid var(--primary); font-weight: bold; }
        .btn { flex: 1; padding: 8px; border-radius: 6px; text-align: center; text-decoration: none; font-weight: bold; cursor: pointer; font-size: 0.8rem; border: none; color: #fff; }
        .pub { background: var(--primary); } .shr { background: var(--success); }
        h3 { font-size: 1.1rem; margin: 15px 0 10px 0; border-bottom: 2px solid #eee; padding-bottom: 5px; }
    </style>
</head>
<body>
    <div class="card" style="text-align:center;">
        <h1 style="margin:0; font-size:1.4rem;">ğŸ¥ GI Intel Terminal</h1>
        <small style="font-size:0.75rem;">Updated: 2026-03-01 14:11 KST</small>
    </div>
    
    <div class="card" style="border-top: 5px solid #e74c3c;">
        <h2 style="margin-top:0; font-size:1rem; color:#e74c3c;">ğŸ”¥ Weekly Top 3 (Practice-Changing)</h2>
        
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a poor prognosis due to late diagnosis and limited treatment options. The secretome, encompassing proteins, metabolites, and extracellular vesicles secreted by cells, has emerged as a promising tool for early detection, risk stratification, and therapeutic targeting in HCC. Recent studies suggest that secretome-derived biomarkers improve diagnostic accuracy and predict survival outcomes. However, variability in methodologies and findings necessitates a comprehensive synthesis of evidence.<br><br>A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and Scopus databases were searched on 2 May 2025 for studies evaluating the diagnostic and prognostic value of the secretome in HCC. Eligibility criteria included original research reporting sensitivity, specificity, or survival outcomes. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. Pooled estimates of sensitivity, specificity, and hazard ratios (HRs) were calculated using random-effects models, with heterogeneity assessed via IÂ² statistics.<br><br>Five studies met the inclusion criteria. The secretome demonstrated high diagnostic accuracy, with a pooled sensitivity of 95.9% [95% confidence intervals (CI): 40-100] and specificity of 89.6% (95% CI: 43.1-99). Moderate heterogeneity (IÂ² = 44%) was observed. For survival outcomes, the pooled HR was 2.37 (95% CI: 0.87-6.41), though statistical significance was not reached (Pâ€…=â€…0.07).<br><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757612/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757612')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757612" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757612/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"><span class='badge if'>IF 9.3</span> <b>Endoscopy</b> <span class='badge rct'>RCT</span> âš ï¸</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ PPI ì „ëµ ì¬í‰ê°€</div>
        <div><b>âš¡ Action:</b> âš ï¸ ê¸°ì¡´ ìœ ì§€ ê¶Œì¥</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Endoscopic submucosal dissection (ESD) is a minimally invasive and effective treatment for large nonpedunculated colorectal polyps; however, it carries a relevant risk of adverse events (AEs), such as delayed bleeding, as well as postprocedural perforation (PPP) and postelectrocoagulation syndrome (PECS). Systematic defect closure may reduce these risks, but its preventive efficacy remains uncertain. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prophylactic clipping after colorectal ESD.Following PRISMA guidelines, we searched MEDLINE, Embase, and SCOPUS through to June 2025 for RCTs comparing prophylactic clipping vs. no clipping after colorectal ESD in adults. The primary outcome was clinically significant delayed bleeding; secondary outcomes included PPP and PECS, as well as subanalysis by location and size. Random-effects models were used to compute risk ratios (RRs) and 95%CIs.Four RCTs from Asia including 684 patients were analyzed (336 with clipping, 348 controls). Prophylactic clipping significantly reduced clinically significant delayed bleeding risk (0.3% vs. 3.4%; RR 0.26, 95%CI 0.08-0.88). No significant differences were found for PPP (0.4% vs. 1.0%; RR 0.74; 95%CI 0.23-2.35) or PECS (12.2% vs. 11.8%; RR 1.06; 95%CI 0.74-1.52). Subgroup analyses by lesion size (>30 mm vs. <30 mm) and location (proximal vs. distal colon) were not significant.A 74% decrease in the risk of clinically significant delayed bleeding is achieved by prophylactic clipping after colorectal ESD, supporting its adoption in routine practice.</div>
            <div class="abs">Endoscopic submucosal dissection (ESD) is a minimally invasive and effective treatment for large nonpedunculated colorectal polyps; however, it carries a relevant risk of adverse events (AEs), such as delayed bleeding, as well as postprocedural perforation (PPP) and postelectrocoagulation syndrome (PECS). Systematic defect closure may reduce these risks, but its preventive efficacy remains uncertain. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prophylactic clipping after colorectal ESD.Following PRISMA guidelines, we searched MEDLINE, Embase, and SCOPUS through to June 2025 for RCTs comparing prophylactic clipping vs. no clipping after colorectal ESD in adults. The primary outcome was clinically significant delayed bleeding; secondary outcomes included PPP and PECS, as well as subanalysis by location and size. Random-effects models were used to compute risk ratios (RRs) and 95%CIs.Four RCTs from Asia including 684 patients were analyzed (336 with clipping, 348 controls). Prophylactic clipping significantly reduced clinically significant delayed bleeding risk (0.3% vs. 3.4%; RR 0.26, 95%CI 0.08-0.88). No significant differences were found for PPP (0.4% vs. 1.0%; RR 0.74; 95%CI 0.23-2.35) or PECS (12.2% vs. 11.8%; RR 1.06; 95%CI 0.74-1.52). Subgroup analyses by lesion size (>30 mm vs. <30 mm) and location (proximal vs. distal colon) were not significant.A 74% decrease in the risk of clinically significant delayed bleeding is achieved by prophylactic clipping after colorectal ESD, supporting its adoption in routine practice.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760121/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760121')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760121" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis.\nğŸ¥ Endoscopy\nâš¡ âš ï¸ ê¸°ì¡´ ìœ ì§€ ê¶Œì¥\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760121/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Frontiers in genetics</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="abs">ctDNA is a promising biomarker in oncology. However, its prognostic and predictive value in HCC remains underexplored. This meta-analysis aims to evaluate the prognostic impact of ctDNA in HCC and its predictive value for recurrence.<br><br>A systematic review and meta-analysis were performed following PRISMA guidelines. PubMed, Embase, Web of Science, and CNKI were searched up to 1 June 2025, for studies assessing ctDNA in HCC patients with reported survival outcomes or predictive accuracy. Studies reporting hazard ratios for overall or disease-free survival, or AUCs for prediction, were included. Two reviewers independently screened studies and assessed quality using the Newcastle-Ottawa Scale (NOS). Meta-analyses used random- or fixed-effects models depending on heterogeneity, with sensitivity analyses performed to assess robustness.<br><br>A total of 219 records were screened from PubMed, Embase, Web of Science, and CNKI, and 8 studies comprising 1,907 patients were included. ctDNA positivity was significantly associated with poorer OS, with a pooled HR of 2.34 (95% CI 1.96-2.78; p < 0.0001). Moderate heterogeneity was observed (I<br><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757268/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757268')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757268" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.\nğŸ¥ Frontiers in genetics\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757268/</textarea>
        </div>
    </details>
    </div>

    <div class="chart-container">
        <canvas id="c2"></canvas>
    </div>

    <div class="card">
        <button id="fBtn" onclick="toggleF()" style="width:100%; padding:10px; border-radius:20px; border:1px solid var(--success); background:#fff; color:var(--success); font-weight:bold; cursor:pointer; font-size: 0.85rem;">ğŸ“‹ ê°€ì´ë“œë¼ì¸ë§Œ ë³´ê¸°</button>
        <div class='sec-group'><h3>ğŸ GI Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 9.3</span> <b>Endoscopy</b> <span class='badge rct'>RCT</span> âš ï¸</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ PPI ì „ëµ ì¬í‰ê°€</div>
        <div><b>âš¡ Action:</b> âš ï¸ ê¸°ì¡´ ìœ ì§€ ê¶Œì¥</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Endoscopic submucosal dissection (ESD) is a minimally invasive and effective treatment for large nonpedunculated colorectal polyps; however, it carries a relevant risk of adverse events (AEs), such as delayed bleeding, as well as postprocedural perforation (PPP) and postelectrocoagulation syndrome (PECS). Systematic defect closure may reduce these risks, but its preventive efficacy remains uncertain. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prophylactic clipping after colorectal ESD.Following PRISMA guidelines, we searched MEDLINE, Embase, and SCOPUS through to June 2025 for RCTs comparing prophylactic clipping vs. no clipping after colorectal ESD in adults. The primary outcome was clinically significant delayed bleeding; secondary outcomes included PPP and PECS, as well as subanalysis by location and size. Random-effects models were used to compute risk ratios (RRs) and 95%CIs.Four RCTs from Asia including 684 patients were analyzed (336 with clipping, 348 controls). Prophylactic clipping significantly reduced clinically significant delayed bleeding risk (0.3% vs. 3.4%; RR 0.26, 95%CI 0.08-0.88). No significant differences were found for PPP (0.4% vs. 1.0%; RR 0.74; 95%CI 0.23-2.35) or PECS (12.2% vs. 11.8%; RR 1.06; 95%CI 0.74-1.52). Subgroup analyses by lesion size (>30 mm vs. <30 mm) and location (proximal vs. distal colon) were not significant.A 74% decrease in the risk of clinically significant delayed bleeding is achieved by prophylactic clipping after colorectal ESD, supporting its adoption in routine practice.</div>
            <div class="abs">Endoscopic submucosal dissection (ESD) is a minimally invasive and effective treatment for large nonpedunculated colorectal polyps; however, it carries a relevant risk of adverse events (AEs), such as delayed bleeding, as well as postprocedural perforation (PPP) and postelectrocoagulation syndrome (PECS). Systematic defect closure may reduce these risks, but its preventive efficacy remains uncertain. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prophylactic clipping after colorectal ESD.Following PRISMA guidelines, we searched MEDLINE, Embase, and SCOPUS through to June 2025 for RCTs comparing prophylactic clipping vs. no clipping after colorectal ESD in adults. The primary outcome was clinically significant delayed bleeding; secondary outcomes included PPP and PECS, as well as subanalysis by location and size. Random-effects models were used to compute risk ratios (RRs) and 95%CIs.Four RCTs from Asia including 684 patients were analyzed (336 with clipping, 348 controls). Prophylactic clipping significantly reduced clinically significant delayed bleeding risk (0.3% vs. 3.4%; RR 0.26, 95%CI 0.08-0.88). No significant differences were found for PPP (0.4% vs. 1.0%; RR 0.74; 95%CI 0.23-2.35) or PECS (12.2% vs. 11.8%; RR 1.06; 95%CI 0.74-1.52). Subgroup analyses by lesion size (>30 mm vs. <30 mm) and location (proximal vs. distal colon) were not significant.A 74% decrease in the risk of clinically significant delayed bleeding is achieved by prophylactic clipping after colorectal ESD, supporting its adoption in routine practice.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760121/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760121')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760121" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis.\nğŸ¥ Endoscopy\nâš¡ âš ï¸ ê¸°ì¡´ ìœ ì§€ ê¶Œì¥\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760121/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of laparoendoscopic & advanced surgical techniques. Part A</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>All five procedures demonstrate durable weight loss at 10+ years, with a clear hierarchy favoring malabsorptive procedures for weight loss efficacy. Procedure selection should consider patient-specific factors, including baseline BMI, presence of GERD, metabolic comorbidities, and capacity for long-term nutritional follow-up.</div>
            <div class="abs">Metabolic and bariatric surgery is the most effective treatment for severe obesity. While short- and mid-term results are well documented, very long-term data (â‰¥10 years) remain scarce, particularly for newer procedures. This review aims to synthesize the available evidence on weight loss outcomes, comorbidity resolution, and complications at 10 years and beyond for the five main bariatric procedures.<br><br>A comprehensive literature review was performed using PubMed, MEDLINE, and Cochrane databases. Studies reporting outcomes at â‰¥10 years for sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), one-anastomosis gastric bypass (OAGB), biliopancreatic diversion with duodenal switch (BPD-DS), and single-anastomosis duodeno-ileal bypass with sleeve (SADI-S) were included.<br><br>At 10 years, weighted mean %TWL ranged from 24.4% for SG to approximately 40% for BPD-DS. The SLEEVEPASS randomized controlled trial demonstrated superior weight loss with RYGB compared to SG (%EWL 51.9% versus 43.5%, <br><br>All five procedures demonstrate durable weight loss at 10+ years, with a clear hierarchy favoring malabsorptive procedures for weight loss efficacy. Procedure selection should consider patient-specific factors, including baseline BMI, presence of GERD, metabolic comorbidities, and capacity for long-term nutritional follow-up.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41762074/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41762074')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41762074" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond.\nğŸ¥ Journal of laparoendoscopic & advanced surgical techniques. Part A\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41762074/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Healthcare (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41753958/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41753958')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41753958" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.\nğŸ¥ Healthcare (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41753958/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>BMC cancer</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>UHRF2 related to sumoylation : assessment of its role in immune suppression and therapeutic potential in colorectal cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>SUMOylation is a critical post-translational modification of proteins. However, the roles of SUMOylation-related genes in regulating the tumor immune microenvironment and their potential as therapeutic targets in CRC remain unclear. We integrated transcriptomic data from TCGA and GEO to identify 200 SUMOylation-related genes associated with prognosis. Among these, 58 genes exhibiting significant survival differences were selected and classified into three distinct clusters. Cluster C patients have the worst prognosis, linked to increased tumor proliferation and weakened immune responses. The LASSO combined with Random Survival Forest (RSF) approach demonstrated optimal performance in ten machine learning algorithms, yielding the highest C-index (0.715). Subsequently, six key genes-SENP7, NUP85, UHRF2, BRCA1, TOPORS, and SENP5-were selected using the LASSO-RSF framework to develop a refined prognostic model. This model demonstrated high predictive accuracy, with 1-, 3-, and 5-year overall survival AUC values of 0.943, 0.961, and 0.981, respectively. Furthermore, the risk score derived from the model was significantly correlated not only with tumor metastasis and recurrence, advanced tumor stage, and patient age, but also with immune cell infiltration, tumor mutational burden, and sensitivity to anticancer drugs. Single-cell analysis revealed that the core gene UHRF2 is highly expressed in CD8â€‰+â€‰exhausted T cells, but exhibits low expression in conventional CD8â€‰+â€‰T cells and natural killer cells. Experimental data demonstrated that UHRF2 was upregulated in CRC and linked to poor prognosis. Silencing UHRF2 markedly inhibited both proliferation and migration of tumor cells in vitro, as well as tumor growth in vivo. In conclusion, the prognostic model derived from SUMOylation-related genes demonstrates robust predictive accuracy for patient outcomes. UHRF2 is associated with immunosuppression and promotes CRC progression, positioning it as a promising therapeutic target in CRC.</div>
            <div class="abs">SUMOylation is a critical post-translational modification of proteins. However, the roles of SUMOylation-related genes in regulating the tumor immune microenvironment and their potential as therapeutic targets in CRC remain unclear. We integrated transcriptomic data from TCGA and GEO to identify 200 SUMOylation-related genes associated with prognosis. Among these, 58 genes exhibiting significant survival differences were selected and classified into three distinct clusters. Cluster C patients have the worst prognosis, linked to increased tumor proliferation and weakened immune responses. The LASSO combined with Random Survival Forest (RSF) approach demonstrated optimal performance in ten machine learning algorithms, yielding the highest C-index (0.715). Subsequently, six key genes-SENP7, NUP85, UHRF2, BRCA1, TOPORS, and SENP5-were selected using the LASSO-RSF framework to develop a refined prognostic model. This model demonstrated high predictive accuracy, with 1-, 3-, and 5-year overall survival AUC values of 0.943, 0.961, and 0.981, respectively. Furthermore, the risk score derived from the model was significantly correlated not only with tumor metastasis and recurrence, advanced tumor stage, and patient age, but also with immune cell infiltration, tumor mutational burden, and sensitivity to anticancer drugs. Single-cell analysis revealed that the core gene UHRF2 is highly expressed in CD8â€‰+â€‰exhausted T cells, but exhibits low expression in conventional CD8â€‰+â€‰T cells and natural killer cells. Experimental data demonstrated that UHRF2 was upregulated in CRC and linked to poor prognosis. Silencing UHRF2 markedly inhibited both proliferation and migration of tumor cells in vitro, as well as tumor growth in vivo. In conclusion, the prognostic model derived from SUMOylation-related genes demonstrates robust predictive accuracy for patient outcomes. UHRF2 is associated with immunosuppression and promotes CRC progression, positioning it as a promising therapeutic target in CRC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41761142/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41761142')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41761142" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ UHRF2 related to sumoylation : assessment of its role in immune suppression and therapeutic potential in colorectal cancer.\nğŸ¥ BMC cancer\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41761142/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in oncology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The clinical research and development activities of BsAbs in the field of CRC treatment are becoming increasingly active and mature. Currently, the focus is on establishing a safety profile. Dual-target blocking based on PD-1 and strategies targeting EGFR/cMET are the current main research and development directions. In contrast to resource-intensive CAR-T or payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinct practical and mechanistic benefits. In the future, it is necessary to further optimize the design of BsAbs, explore combination therapies and identify predictive biomarkers to promote its clinical transformation and improve the prognosis of CRC patients.</div>
            <div class="abs">Colorectal cancer (CRC) is a malignant tumor with a high incidence and mortality rate worldwide. The existing treatment methods have limitations in terms of efficacy or applicable population. Bispecific antibodies (BsAbs) can simultaneously target two different antigens and are expected to overcome tumor immune escape, providing a new strategy for the treatment of CRC.<br><br>This study systematically retrieved clinical trial registration platforms such as Trialtrove and ClinicalTrials.gov up to July and November 2025, and collected trial data on the treatment of CRC with BsAbs. Descriptive analyses were conducted on key indicators such as the stage distribution, primary endpoints, funding types, global distribution, and target combinations of the trials by establishing clear inclusion and exclusion criteria.<br><br>A total of 192 clinical trials were included. Since 2018, the number of related trials has significantly increased, and the trial phase has shifted from mainly Phase I in the early stage to a substantial growth in Phase II and Phase III trials after 2023-2024. The primary endpoints of the trial were highly concentrated on safety assessment (such as safety/tolerability, adverse events). The industrial sector is the main funder (68.3%), and the number of trials conducted in China (n=125) ranks first in the world. The target combinations are most commonly PD-1/CTLA-4 and PD-1/VEGF, and studies on novel combinations such as EGFR/cMET are also on the rise. Efficacy data from key trials (e.g., Cadonilimab, Amivantamab) demonstrate encouraging response rates in both locally advanced and metastatic settings, particularly in MSS/pMMR populations.<br><br>The clinical research and development activities of BsAbs in the field of CRC treatment are becoming increasingly active and mature. Currently, the focus is on establishing a safety profile. Dual-target blocking based on PD-1 and strategies targeting EGFR/cMET are the current main research and development directions. In contrast to resource-intensive CAR-T or payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinct practical and mechanistic benefits. In the future, it is necessary to further optimize the design of BsAbs, explore combination therapies and identify predictive biomarkers to promote its clinical transformation and improve the prognosis of CRC patients.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41756334/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41756334')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41756334" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps.\nğŸ¥ Frontiers in oncology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41756334/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Genetics</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Detecting and Quantifying Networks of Biological Kinship via Exponential Family Random Graph Models.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Genetic relatedness between ancient humans can help to identify close and distant connections between groups and populations, uncovering signatures of demographic histories such as identifying mating networks or long-range migration. Critical to researchers are the characteristics that connected individuals, or groups of individuals, share, and how these characteristics interact and are correlated. Here we use Exponential Random Graph models as a method to explore demographic and contextual parameters that may help to explain the significant drivers of the topology of mating networks, as well as to quantify their effects. We show through simulations that model selection and coefficient estimators facilitate the exploration of such networks, and apply the method to individuals from a collection of Avar-associated cemeteries from the Carpathian Basin dating to the 6th to the 9th centuries CE.</div>
            <div class="abs">Genetic relatedness between ancient humans can help to identify close and distant connections between groups and populations, uncovering signatures of demographic histories such as identifying mating networks or long-range migration. Critical to researchers are the characteristics that connected individuals, or groups of individuals, share, and how these characteristics interact and are correlated. Here we use Exponential Random Graph models as a method to explore demographic and contextual parameters that may help to explain the significant drivers of the topology of mating networks, as well as to quantify their effects. We show through simulations that model selection and coefficient estimators facilitate the exploration of such networks, and apply the method to individuals from a collection of Avar-associated cemeteries from the Carpathian Basin dating to the 6th to the 9th centuries CE.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41762131/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41762131')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41762131" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Detecting and Quantifying Networks of Biological Kinship via Exponential Family Random Graph Models.\nğŸ¥ Genetics\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41762131/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of managed care & specialty pharmacy</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Biologic dose escalation in inflammatory bowel disease in the United States.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ Dose escalation ê³ ë ¤</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.</div>
            <div class="abs">Treatment for inflammatory bowel disease (IBD), composed of Crohn disease (CD) and ulcerative colitis (UC), frequently employs biologics to help control inflammation, reduce symptom burden, and limit disease progression. Because of both the lifelong, progressive nature of disease and potential for loss of therapy response over time, therapy changes are common. Biologic dose escalation is one method to adjust therapy regimens following loss of response.<br><br>To assess the occurrence of dose escalation in CD and UC and its influence on health care costs.<br><br>Adults with a diagnosis of CD or UC newly initiating therapy with a biologic (adalimumab, infliximab, ustekinumab, vedolizumab, or tofacitinib [UC only]) from January 1, 2017, to June 30, 2022, were selected in the Merative MarketScan Commercial and Medicare Databases. The first claim for the biologic served as the index date and patients were followed over a 12-month pre-period and a 12-month-or-longer post-period. Dose escalation during the maintenance phase of therapy, discontinuation, and postdiscontinuation switching were assessed in biologic-based subgroups in each of the CD and UC cohorts; per-patient-per-month (PPPM) IBD-related health care costs over the duration of index biologic treatment were also calculated.<br><br>Analyses included 6,056 patients with CD (33.5% adalimumab, 30.6% ustekinumab, 18.8% infliximab, 17.1% vedolizumab) and 4,533 patients with UC (35.1% vedolizumab, 30.6% adalimumab, 16.8% infliximab, 10.0% ustekinumab, 7.5% tofacitinib). Dose escalation occurred in 30.4% of patients with CD (adalimumab 20.8%, infliximab 48.8%, ustekinumab 26.9%, vedolizumab 36.2%) and 30.1% of patients with UC (adalimumab 23.0%, infliximab 44.8%, ustekinumab 25.5%, vedolizumab 31.8%, tofacitinib 24.9%). Patients with evidence of dose escalation had lower rates of discontinuation compared with nonescalators over follow-up but were more likely to switch biologics after discontinuation. PPPM IBD-related health care costs over the course of treatment were substantial and largely driven by index biologic costs. Mean PPPM costs for the CD cohort ranged from $4,543 in the infliximab group to $14,031 in the ustekinumab group; costs were similar in the UC cohort, ranging from $5,213 in the infliximab group to $14,246 in the ustekinumab group. Within both cohorts, dose escalation was a significant predictor of increased IBD-related health care costs.<br><br>Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760568/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760568')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760568" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Biologic dose escalation in inflammatory bowel disease in the United States.\nğŸ¥ Journal of managed care & specialty pharmacy\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760568/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in nutrition</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>There may be a differential mechanistic impact on colorectal cancer of lactose-containing foods between lactase persistent and lactase non-persistent populations.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>It is generally suggested that milk and milk products reduce the risk of colorectal cancer (CRC). While there is some controversy over specific sites affected throughout the colon and the benefits of specific dairy foods (DFs), there is a general consensus that calcium intake is the main mechanism of the cancer-reducing effects. This opinion may be sidelined by several other mechanisms. There is also a potentially important compensatory mechanism in populations with adult genetic lactase deficiency. The microbiome changes occur through a process of adaptation to continued lactose consumption. The bacterial blooms consist largely of </div>
            <div class="abs">It is generally suggested that milk and milk products reduce the risk of colorectal cancer (CRC). While there is some controversy over specific sites affected throughout the colon and the benefits of specific dairy foods (DFs), there is a general consensus that calcium intake is the main mechanism of the cancer-reducing effects. This opinion may be sidelined by several other mechanisms. There is also a potentially important compensatory mechanism in populations with adult genetic lactase deficiency. The microbiome changes occur through a process of adaptation to continued lactose consumption. The bacterial blooms consist largely of </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41756623/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41756623')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41756623" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ There may be a differential mechanistic impact on colorectal cancer of lactose-containing foods between lactase persistent and lactase non-persistent populations.\nğŸ¥ Frontiers in nutrition\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41756623/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Diabetes, obesity & metabolism</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Metformin may prevent colorectal cancer via the AMPKÎ³1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.</div>
            <div class="abs">Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug-target Mendelian randomization (MR) design.<br><br>We identified genetic proxies of 11 metformin targets (PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, ETFDH, GPD1, SLC47A1 and ACACB) based on their associations with tissue-specific gene expression, overall/sex-specific HbA1c and type 2 diabetes. We then evaluated genetically proxied effects of these targets on five major cancers using MR. We also employed a conventional MR design to assess the relationship of HbA1c with cancer using the inverse variance method, with sensitivity analyses. Associations were corrected for multiple comparisons using false discovery rates.<br><br>We identified two genetic proxies of putative metformin targets (PRKAG1 and GPD1) as valid instrumental variables (F statistics >â€‰10). PRKAG1 was associated with a reduced risk of colorectal cancer (OR: 0.74 per mmol/mol reduction in overall HbA1c, 95% CI: 0.63-0.87; pâ€‰=â€‰0.001), with consistent findings in sex-specific analysis. This effect was unlikely mediated by HbA1c reduction, as indicated by conventional MR analyses (OR: 1.01 per mmol/mol, 95% CI: 0.99-1.02). No significant association was observed for GPD1 (OR: 1.00, 95% CI: 0.74-1.36; pâ€‰=â€‰0.98).<br><br>Metformin may prevent colorectal cancer via the AMPKÎ³1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41755790/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41755790')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41755790" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.\nğŸ¥ Diabetes, obesity & metabolism\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41755790/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸº Liver Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a poor prognosis due to late diagnosis and limited treatment options. The secretome, encompassing proteins, metabolites, and extracellular vesicles secreted by cells, has emerged as a promising tool for early detection, risk stratification, and therapeutic targeting in HCC. Recent studies suggest that secretome-derived biomarkers improve diagnostic accuracy and predict survival outcomes. However, variability in methodologies and findings necessitates a comprehensive synthesis of evidence.<br><br>A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and Scopus databases were searched on 2 May 2025 for studies evaluating the diagnostic and prognostic value of the secretome in HCC. Eligibility criteria included original research reporting sensitivity, specificity, or survival outcomes. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. Pooled estimates of sensitivity, specificity, and hazard ratios (HRs) were calculated using random-effects models, with heterogeneity assessed via IÂ² statistics.<br><br>Five studies met the inclusion criteria. The secretome demonstrated high diagnostic accuracy, with a pooled sensitivity of 95.9% [95% confidence intervals (CI): 40-100] and specificity of 89.6% (95% CI: 43.1-99). Moderate heterogeneity (IÂ² = 44%) was observed. For survival outcomes, the pooled HR was 2.37 (95% CI: 0.87-6.41), though statistical significance was not reached (Pâ€…=â€…0.07).<br><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757612/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757612')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757612" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757612/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in genetics</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="abs">ctDNA is a promising biomarker in oncology. However, its prognostic and predictive value in HCC remains underexplored. This meta-analysis aims to evaluate the prognostic impact of ctDNA in HCC and its predictive value for recurrence.<br><br>A systematic review and meta-analysis were performed following PRISMA guidelines. PubMed, Embase, Web of Science, and CNKI were searched up to 1 June 2025, for studies assessing ctDNA in HCC patients with reported survival outcomes or predictive accuracy. Studies reporting hazard ratios for overall or disease-free survival, or AUCs for prediction, were included. Two reviewers independently screened studies and assessed quality using the Newcastle-Ottawa Scale (NOS). Meta-analyses used random- or fixed-effects models depending on heterogeneity, with sensitivity analyses performed to assess robustness.<br><br>A total of 219 records were screened from PubMed, Embase, Web of Science, and CNKI, and 8 studies comprising 1,907 patients were included. ctDNA positivity was significantly associated with poorer OS, with a pooled HR of 2.34 (95% CI 1.96-2.78; p < 0.0001). Moderate heterogeneity was observed (I<br><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757268/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757268')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757268" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.\nğŸ¥ Frontiers in genetics\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757268/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Type 2 diabetes mellitus and liver diseases: a phenome-wide Mendelian randomization atlas and genome-wide genetic correlation study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Our research has comprehensively revealed the clear causal relationship between T2DM and specific liver diseases, emphasizing the importance of preventing such diseases in patients with T2DM. These findings not only confirm and expand the existing knowledge framework regarding the relationship between T2DM and liver diseases but also provide new insights for clinical practice and future research directions.</div>
            <div class="abs">The causal relationship between type 2 diabetes mellitus (T2DM) and the various liver disease phenotypes remains uncertain.<br><br>Our study provides a comprehensive causal atlas by assessing the causal roles of T2DM across 12 major liver conditions using summary data from genome-wide association studies.<br><br>Our study indicated significant genetic correlations between T2DM and five types of liver diseases, with suggestive levels for three additional types. Furthermore, we found evidence of the causal effects of T2DM on seven types of liver diseases. Specifically, T2DM showed significant causality with metabolic dysfunction-associated steatotic liver disease [odds ratio (OR) = 1.49, 95% confidence interval (CI): 1.37-1.62, P = 2.55â€‰Ã—â€‰10-21], cirrhosis of liver (OR = 1.18, 95% CI: 1.05-1.33, P = 3.98â€‰Ã—â€‰10-3), chronic hepatitis (OR = 1.20, 95% CI: 1.06-1.37, P = 3.72â€‰Ã—â€‰10-3), and hepatocellular carcinoma (OR = 1.31, 95% CI: 1.10-1.56, P = 3.02â€‰Ã—â€‰10-3). In addition, suggestive causality was found between T2DM and nonalcoholic steatohepatitis (OR = 1.45, 95% CI: 1.08-1.95, P = 0.012), fibrosis of liver (OR = 1.47, 95% CI: 1.08-2.00, P = 0.015), and malignant liver neoplasm (OR = 1.21, 95% CI: 1.04-1.42, P = 0.013).<br><br>Our research has comprehensively revealed the clear causal relationship between T2DM and specific liver diseases, emphasizing the importance of preventing such diseases in patients with T2DM. These findings not only confirm and expand the existing knowledge framework regarding the relationship between T2DM and liver diseases but also provide new insights for clinical practice and future research directions.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757613/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757613')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757613" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Type 2 diabetes mellitus and liver diseases: a phenome-wide Mendelian randomization atlas and genome-wide genetic correlation study.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757613/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>European journal of cancer (Oxford, England : 1990)</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This large, single-center study demonstrated that PBT provided favorable local control and survival outcomes, supporting its role as a promising local ablative modality to address the unmet therapeutic needs in HCC.</div>
            <div class="abs">Since December 2015, the Proton Beam Therapy (PBT) center at Samsung Medical Center has treated 2000 cases involving 1823 patients with HCC who were ineligible for Barcelona Clinic Liver Cancer (BCLC) guideline-recommended standard treatments. This study evaluated clinical outcomes and explored the potential role of PBT as an alternative local modality.<br><br>We retrospectively reviewed patients with HCC treated with PBT. The primary endpoint was freedom from local progression (FFLP), and the secondary endpoints were overall survival (OS) and toxicity.<br><br>The annual number of PBT cases increased, among all cases, 93.0â€¯% targeted intrahepatic lesions, while 7.0â€¯% targeted extrahepatic lesions. FFLP was evaluated in intrahepatic cases with a median follow-up of 19.5 months (interquartile range [IQR], 8.5-39.7). The 2-year FFLP exceeded 90â€¯% across the treatment periods without significant differences (Pâ€¯=â€¯0.51). According to the BCLC stages (0, A, B, and C), the 2-year FFLP rates were 95.5â€¯%, 93.9â€¯%, 98.5â€¯%, and 87.6â€¯%, respectively, and the 3-year FFLP rates were 91.1â€¯%, 91.3â€¯%, 95.0â€¯%, and 83.3â€¯%, respectively (Pâ€¯<â€¯0.001). The median OS follow-up was 18.7 months (IQR 7.9-38.6). The 3-year OS rates were 81.1â€¯% in BCLC stage 0; 65.5â€¯%, stage A; 45.5â€¯%, stage B; and 37.2â€¯%, stage C, respectively (Pâ€¯<â€¯0.001).<br><br>This large, single-center study demonstrated that PBT provided favorable local control and survival outcomes, supporting its role as a promising local ablative modality to address the unmet therapeutic needs in HCC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41759412/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41759412')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41759412" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach.\nğŸ¥ European journal of cancer (Oxford, England : 1990)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41759412/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The American journal of managed care</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Quality of life: the pending outcome in idiopathic pulmonary fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="abs">Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41759200/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41759200')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41759200" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Quality of life: the pending outcome in idiopathic pulmonary fibrosis.\nğŸ¥ The American journal of managed care\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41759200/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Nature communications</b> <span class='badge rct'>RCT</span></div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760669/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760669')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760669" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.\nğŸ¥ Nature communications\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760669/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Pediatric surgery international</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Hypoxia-conditioned umbilical cord mesenchymal stem cell secretome attenuates hepatic fibrosis in a bile duct ligation model of biliary atresia.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hypoxia-conditioned UC-MSC secretome improved hepatic function and mitigated fibrosis in the BDL model through suppression of profibrotic and inflammatory mediators. These findings support HU-UCMSC secretome as a safe, cell-free therapeutic candidate for biliary atresia and related pediatric cholestatic liver diseases.</div>
            <div class="abs">Biliary atresia (BA) is a progressive fibro-inflammatory cholangiopathy and the leading cause of neonatal cholestasis and pediatric liver transplantation. Mesenchymal stem cell (MSC)-derived secretome has emerged as promising acellular alternative to cell therapy. This study evaluated the potential of hypoxia-conditioned umbilical cord MSC (HU-UCMSC) secretome in rat model of biliary fibrosis induced by bile duct ligation (BDL).<br><br>Twenty-four male Sprague-Dawley rats were randomized into six groups: Sham, BDL, BDLâ€‰+â€‰vehicle, and BDL treated with HU-UCMSC secretome at doses of 100, 200, and 400 Î¼L. Serum biochemical markers and hepatic gene expression were analyzed using photometry and RT-qPCR. Histopathology and fibrosis fraction area were evaluated by Sirius Red staining.<br><br>HU-UCMSC secretome produced dose-dependent hepatoprotection, significantly reducing SGOT, SGPT, and total bilirubin levels compared with untreated BDL rats. Histologically, collagen deposition and fibrosis fraction area were markedly reduced. Gene expression analysis showed significant downregulation of PDGF, Î±-SMA, and TNF-Î±, with context-dependent modulation of TGF-Î² and VEGF.<br><br>Hypoxia-conditioned UC-MSC secretome improved hepatic function and mitigated fibrosis in the BDL model through suppression of profibrotic and inflammatory mediators. These findings support HU-UCMSC secretome as a safe, cell-free therapeutic candidate for biliary atresia and related pediatric cholestatic liver diseases.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41758387/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41758387')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41758387" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Hypoxia-conditioned umbilical cord mesenchymal stem cell secretome attenuates hepatic fibrosis in a bile duct ligation model of biliary atresia.\nğŸ¥ Pediatric surgery international\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41758387/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Veterinary medicine and science</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Economic Impact and Disease Insights: Understanding Organ Condemnation in Cattle Slaughtered at Bahir Dar Abattoir.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The current study implies that there was considerable edible offal condemnation resulting in significant economic loss. This instigates that it is crucial to adopt efficient animal management practices, conduct regular health assessments of animals and provide educational programmes for animal owners on disease prevention strategies like deworming to reduce the incidence of organ condemnation and its financial impacts in the region.</div>
            <div class="abs">Abattoir surveillance is the font of valuable information on the incidence and epidemiology of animal disease, having both public and animal health importance. A cross-sectional study followed by simple random sampling was conducted from December 2021 to May 2022 to identify the major causes of edible offal condemnation and to estimate the financial losses attributed to edible offal condemnation in cattle slaughtered at Bahir Dar municipal abattoir, northwestern Ethiopia, using antemortem and post-mortem examination.<br><br>Out of 334 cattle investigated, 3.6% (12/334) cattle showed detectable abnormalities including diarrhoea in 0.6% (2/12), lameness in 0.9% (3/12) and tick infestation in 1.2% (4/12), and nasal discharge in 0.9% (3/12) in cattle during an antemortem examination. However, in post-mortem examination, 22.16% (74/334) of cattle revealed lesions in visceral organs including the liver (14.6%), lung (9.9%), kidney (1.8%), heart (2.4%) and tongue (0.9%). The major causes that were identified in the current study include calcification, fasciolosis, hydatid cyst, cirrhosis, abscess, pneumonia, haemorrhage, emphysema, congestion, pericarditis, Cysticercus bovis, nephritis and renal calculi. Among the putative risk factors, only body condition was shown to have statistically significant variation (pÂ <Â 0.05) with the prevalence of major causes of organ condemnation upon post-mortem examination. The overall financial losses incurred due to organ condemnation were estimated to be $475.19, with an annual loss of $15,447.85.<br><br>The current study implies that there was considerable edible offal condemnation resulting in significant economic loss. This instigates that it is crucial to adopt efficient animal management practices, conduct regular health assessments of animals and provide educational programmes for animal owners on disease prevention strategies like deworming to reduce the incidence of organ condemnation and its financial impacts in the region.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41758074/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41758074')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41758074" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Economic Impact and Disease Insights: Understanding Organ Condemnation in Cattle Slaughtered at Bahir Dar Abattoir.\nğŸ¥ Veterinary medicine and science\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41758074/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Microbiology spectrum</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The regional landscape of the human colon culturome in health and cystic fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This pilot study of a small cohort represents the first culturome analysis of the cystic fibrosis colon. Our preliminary findings demonstrate that cystic fibrosis (CF)-associated gut dysbiosis is spatially specific, with mucosal bacterial communities showing pronounced alterations while luminal communities show comparatively subtle phylum-specific shifts. This spatial specificity suggests the mucosal microenvironment as a potential therapeutic target and indicates that interventions focused solely on luminal bacteria may be insufficient. The promising predictive accuracy of culturome-based machine learning models in this small cohort suggests these viable bacterial signatures could serve as biomarkers for CF management pending larger validation studies. Additionally, our initial observations of CFTR modulator effects on gut microbial communities provide insight for future studies optimizing combination therapies.</div>
            <div class="abs">Cystic fibrosis (CF) alters gut physiology, yet its impact on microbial communities across colonic regions (ascending, transverse, descending colon) and microhabitats (lumen, mucosa) remains incompletely understood. Here, we applied culturomics to characterize gut microbiota in a small cohort of 32 individuals (22 non-CF, 10 CF). Persons with CF (pwCF) exhibited significantly higher viable bacterial loads than non-CF individuals, particularly in mucosal samples. Anaerobes predominated overall, with relative enrichment of aerobes in the mucosa of pwCF. Alpha diversity was reduced in mucosal samples and aerobic cultures for pwCF, whereas beta diversity was influenced by all the tested variables except the colonic region. Phylum-level analyses revealed enrichment of Proteobacteria and depletion of Actinobacteria, Bacteroidota, and Firmicutes in samples from pwCF, consistent with stool analysis. Random forest models identified selected oral-associated microbes as key predictive taxa and accurately classified polyp status within this cohort. Whole-genome sequencing of <br><br>This pilot study of a small cohort represents the first culturome analysis of the cystic fibrosis colon. Our preliminary findings demonstrate that cystic fibrosis (CF)-associated gut dysbiosis is spatially specific, with mucosal bacterial communities showing pronounced alterations while luminal communities show comparatively subtle phylum-specific shifts. This spatial specificity suggests the mucosal microenvironment as a potential therapeutic target and indicates that interventions focused solely on luminal bacteria may be insufficient. The promising predictive accuracy of culturome-based machine learning models in this small cohort suggests these viable bacterial signatures could serve as biomarkers for CF management pending larger validation studies. Additionally, our initial observations of CFTR modulator effects on gut microbial communities provide insight for future studies optimizing combination therapies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757945/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757945')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757945" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The regional landscape of the human colon culturome in health and cystic fibrosis.\nğŸ¥ Microbiology spectrum\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757945/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸ§¬ Biliary/Pancreas</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</b> <span class='badge rct'>RCT</span></div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hypertriglyceridemia (HTG) increases cardiovascular and pancreatitis risk. Antisense oligonucleotide (ASO) therapies like volanesorsen and olezarsen target ApoC-III mRNA to reduce ApoC-III, enhancing lipoprotein lipase activity and lowering triglycerides (TGs). This meta-analysis evaluates the efficacy and safety of these ASOs in severe HTG. A systematic review (PROSPERO: CRD42024577110) was conducted following PRISMA, sourcing studies from PubMed, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov until July 2024. Randomized controlled trials (RCTs) involving severe HTG (â‰¥200 mg/dL) treated with volanesorsen or olezarsen vs. placebo were included. Data were synthesized using a random effects model in RevMan 5.4, and bias was assessed with the Cochrane tool. Of 31 identified articles, 9 RCTs (341 patients treated with ASOs, 209 controls) were included. ASOs significantly reduced TG levels [mean difference (MD): -53.72; 95% confidence interval (CI): -77.04 to -30.40; p<0.00001]. Reductions were also seen in very low-density lipoprotein cholesterol (MD: -55.76; p<0.00001), ApoC-III (MD: -74.78; p<0.00001), and APOB48 (MD: -69.45; p<0.00001). Olezarsen uniquely reduced APOB (MD: -15.60; p<0.00001). Non-high-density lipoprotein cholesterol (HDL-C) decreased (MD: -23.25; p<0.00001), while HDL-C increased (MD: +42.14; p<0.00001). Volanesorsen was linked to higher low-density lipoprotein-cholesterol (MD: +62.74; p=0.004). For safety, local injection reactions, thrombocytopenia, and nausea were more common with volanesorsen. Acute pancreatitis occurred only in the placebo group (relative risk: 0.15; p=0.0004), indicating ASO protection. This meta-analysis confirms that ASOs effectively lower TGs and improve lipid profiles in severe HTG.</div>
            <div class="abs">Hypertriglyceridemia (HTG) increases cardiovascular and pancreatitis risk. Antisense oligonucleotide (ASO) therapies like volanesorsen and olezarsen target ApoC-III mRNA to reduce ApoC-III, enhancing lipoprotein lipase activity and lowering triglycerides (TGs). This meta-analysis evaluates the efficacy and safety of these ASOs in severe HTG. A systematic review (PROSPERO: CRD42024577110) was conducted following PRISMA, sourcing studies from PubMed, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov until July 2024. Randomized controlled trials (RCTs) involving severe HTG (â‰¥200 mg/dL) treated with volanesorsen or olezarsen vs. placebo were included. Data were synthesized using a random effects model in RevMan 5.4, and bias was assessed with the Cochrane tool. Of 31 identified articles, 9 RCTs (341 patients treated with ASOs, 209 controls) were included. ASOs significantly reduced TG levels [mean difference (MD): -53.72; 95% confidence interval (CI): -77.04 to -30.40; p<0.00001]. Reductions were also seen in very low-density lipoprotein cholesterol (MD: -55.76; p<0.00001), ApoC-III (MD: -74.78; p<0.00001), and APOB48 (MD: -69.45; p<0.00001). Olezarsen uniquely reduced APOB (MD: -15.60; p<0.00001). Non-high-density lipoprotein cholesterol (HDL-C) decreased (MD: -23.25; p<0.00001), while HDL-C increased (MD: +42.14; p<0.00001). Volanesorsen was linked to higher low-density lipoprotein-cholesterol (MD: +62.74; p=0.004). For safety, local injection reactions, thrombocytopenia, and nausea were more common with volanesorsen. Acute pancreatitis occurred only in the placebo group (relative risk: 0.15; p=0.0004), indicating ASO protection. This meta-analysis confirms that ASOs effectively lower TGs and improve lipid profiles in severe HTG.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41755797/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41755797')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41755797" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.\nğŸ¥ Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41755797/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>BMC infectious diseases</b> <span class='badge rct'>RCT</span></div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Efficacy and safety of levornidazole disodium phosphate injection in patients with intra-abdominal infections caused by anaerobic bacteria: a multicenter, randomized, single-blind, phase IV, non-inferiority trial (ANAEROGUARD study).</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41761107/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41761107')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41761107" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Efficacy and safety of levornidazole disodium phosphate injection in patients with intra-abdominal infections caused by anaerobic bacteria: a multicenter, randomized, single-blind, phase IV, non-inferiority trial (ANAEROGUARD study).\nğŸ¥ BMC infectious diseases\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41761107/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>HPB : the official journal of the International Hepato Pancreato Biliary Association</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Systematic review of randomised controlled trials on pain domains and assessment methods in post pancreatectomy patients.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>There was notable heterogeneity in pain domains assessed and the tools used across pain management RCTs post-pancreatectomy. This highlights the need for standardized core outcome domains and multidimensional tools specific to pancreatic surgery to enable comparability of data and robust analysis.</div>
            <div class="abs">This systematic review aims to identify the core outcome domains and assessment methods currently used in randomised controlled trials (RCTs) for acute postoperative pain following pancreatic surgery.<br><br>PubMed, Embase, Web of Science, and the Cochrane Library were searched without restrictions. Eligible studies were screened and data extracted for pain assessment tools, analgesic outcomes, adverse effects, pain interference and quality-of-life measures.<br><br>Fifteen RCTs involving 1034 patients were included. All trials assessed pain intensity using a visual analogue scale (n = 11) or a numerical rating scale (n = 4). Analgesic consumption was reported in 13 trials, with significant variability in the reporting, rescue analgesia and adverse effects. Pain interference or physical function was described in 10 trials, including pain on coughing (n = 4), mobilisation (n = 3), % gait speed and % peak cough flow (n = 2). Multidimensional tools were rarely used, with a single RCT employing three different scales. Psychological function was assessed in one trial using anxiety and depression scales.<br><br>There was notable heterogeneity in pain domains assessed and the tools used across pain management RCTs post-pancreatectomy. This highlights the need for standardized core outcome domains and multidimensional tools specific to pancreatic surgery to enable comparability of data and robust analysis.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760468/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760468')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760468" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Systematic review of randomised controlled trials on pain domains and assessment methods in post pancreatectomy patients.\nğŸ¥ HPB : the official journal of the International Hepato Pancreato Biliary Association\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760468/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>International journal of cancer</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Tumor Treating Fields (TTFields) are an approved cancer therapy for glioblastoma (GBM), pleural mesothelioma, and non-small cell lung cancer (NSCLC). A recent phase 3 trial of TTFields therapy concomitant with standard-of-care gemcitabine and nab-paclitaxel (Gem/NabP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma demonstrated a significant increase in overall survival. The current study evaluated the effects of TTFields in preclinical pancreatic ductal adenocarcinoma (PDAC) models. The vast majority of PDAC patients harbor KRAS mutations, which are associated with a more aggressive disease phenotype and increased therapy resistance, driven in part by overexpression of the key transcription factor c-Myc. In the current study, TTFields application significantly suppressed c-Myc expression and induced immunogenic cell death (ICD)-characterized by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release-in pancreatic cancer models. These effects were further enhanced when TTFields were applied concomitantly with Gem/NabP. Causality between c-Myc modulation and immune readouts was not established. In vivo, TTFields application induced a systemic immune response, evidenced by dendritic cell activation, increased effector memory T cells, and greater tumor leukocyte infiltration. TTFields concomitant with Gem/NabP significantly reduced tumor volume, decreased tumor monocytic myeloid-derived suppressor cells (M-MDSC), and increased the tumor lymphocyte-to-monocyte ratio (LMR) compared to all other treatment groups. These findings support the potential of TTFields to enhance therapeutic efficacy. Moreover, TTFields-induced tumor immunogenicity may enable combination strategies with immunotherapies. A phase 2 clinical trial investigating TTFields with Gem/NabP and immune checkpoint inhibitors (ICIs) for metastatic PDAC is currently underway.</div>
            <div class="abs">Tumor Treating Fields (TTFields) are an approved cancer therapy for glioblastoma (GBM), pleural mesothelioma, and non-small cell lung cancer (NSCLC). A recent phase 3 trial of TTFields therapy concomitant with standard-of-care gemcitabine and nab-paclitaxel (Gem/NabP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma demonstrated a significant increase in overall survival. The current study evaluated the effects of TTFields in preclinical pancreatic ductal adenocarcinoma (PDAC) models. The vast majority of PDAC patients harbor KRAS mutations, which are associated with a more aggressive disease phenotype and increased therapy resistance, driven in part by overexpression of the key transcription factor c-Myc. In the current study, TTFields application significantly suppressed c-Myc expression and induced immunogenic cell death (ICD)-characterized by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release-in pancreatic cancer models. These effects were further enhanced when TTFields were applied concomitantly with Gem/NabP. Causality between c-Myc modulation and immune readouts was not established. In vivo, TTFields application induced a systemic immune response, evidenced by dendritic cell activation, increased effector memory T cells, and greater tumor leukocyte infiltration. TTFields concomitant with Gem/NabP significantly reduced tumor volume, decreased tumor monocytic myeloid-derived suppressor cells (M-MDSC), and increased the tumor lymphocyte-to-monocyte ratio (LMR) compared to all other treatment groups. These findings support the potential of TTFields to enhance therapeutic efficacy. Moreover, TTFields-induced tumor immunogenicity may enable combination strategies with immunotherapies. A phase 2 clinical trial investigating TTFields with Gem/NabP and immune checkpoint inhibitors (ICIs) for metastatic PDAC is currently underway.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41760592/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41760592')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41760592" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.\nğŸ¥ International journal of cancer\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41760592/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The oncologist</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.</div>
            <div class="abs">Dual mitogen-activated protein kinase (MAPK) pathway and autophagy inhibition shows synergistic antitumor activity in preclinical models of RAS-mutant cancers. We hypothesized that autophagy blockade with hydroxychloroquine (HCQ) could overcome resistance to MEK inhibition with binimetinib (BINI) and provide clinical benefit in previously treated, KRAS-mutated, metastatic pancreatic ductal adenocarcinoma (PDAC).<br><br>This investigator-led, single-arm, open-label, phase I dose escalation/expansion trial evaluated the safety and tolerability of BINI + HCQ in patients with previously treated, metastatic PDAC (NCT04132505). Key eligibility criteria: ECOG 0-1, adequate organ function, â‰¥ 1 prior line of therapy for metastatic disease, and presence of KRAS mutation. Dose escalation followed a Bayesian optimal interval (BOIN) design. The primary endpoint was the maximum tolerated dose (MTD). Secondary endpoints included safety, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).<br><br>From December 2019 to August 2024, 34 patients were enrolled in dose escalation (nâ€‰=â€‰17) and dose expansion (nâ€‰=â€‰17). Two dose-limiting toxicities occurred among the first 3 patients treated at dose level 1 (BINI 45â€‰mg + HCQ 600â€‰mg): grade 3 creatine phosphokinase elevation with renal impairment (BINI) and grade 3â€‰QT prolongation (HCQ). Following dose de-escalation due to poor tolerance, the MTD was determined to be BINI 30â€‰mg + HCQ 600â€‰mg twice daily and used in expansion. Out of 31 response-evaluable patients, 2 patients achieved a partial response and 9 patients achieved stable disease, yielding ORR 6.5% and DCR 35.5%, respectively. Median PFS was 1.9â€‰months, and median OS was 5.3â€‰months.<br><br>The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41761573/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41761573')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41761573" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer.\nğŸ¥ The oncologist\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41761573/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Life (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Genetic Susceptibility to </div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41752920/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41752920')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41752920" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Genetic Susceptibility to \nğŸ¥ Life (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41752920/</textarea>
        </div>
    </details></div>
    </div>

    <footer style="text-align:center; padding:15px; color:#95a5a6; font-size:0.75rem;">ğŸš€ Project: MedProductive Clinical AI</footer>

    <script>
        function toggleF() {
            const btn = document.getElementById('fBtn'); btn.classList.toggle('active');
            const isF = btn.classList.contains('active');
            btn.style.background = isF ? 'var(--success)' : '#fff';
            btn.style.color = isF ? '#fff' : 'var(--success)';
            document.querySelectorAll('.paper-item').forEach(p => {
                p.style.display = isF ? (p.querySelector('.badge-guideline') ? 'block' : 'none') : 'block';
            });
        }
        function copyShare(id) {
            const el = document.getElementById('s_'+id);
            navigator.clipboard.writeText(el.value.replace(/\\n/g, '\n')).then(() => alert("âœ… ë³µì‚¬ ì™„ë£Œ!"));
        }
        
        // ë„ë„› ì°¨íŠ¸ë§Œ ë Œë”ë§
        new Chart(document.getElementById('c2'), { 
            type:'doughnut', 
            data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[9, 9, 6], backgroundColor:['#e74c3c','#f1c40f','#2ecc71']}] }, 
            options: { 
                responsive: true, 
                maintainAspectRatio: false, 
                plugins: { 
                    legend: { position: 'right', labels: { font: { size: 10 } } } 
                } 
            } 
        });
    </script>
</body>
</html>
